Skip to main content

Table 5 Patients with suspected VAP and previous exposure to statins

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

  Statin continuation Statin discontinuation P
(n = 52) (n = 41)
Age (years) 67.5 (27.0-85.0) 68.0 (46.0-90.0) 0.99
SAPS II 51.0 (18.0-109.0) 55.0 (24.0-91.0) 0.56
Gender, male (n (%)) 44 (84.6) 36 (87.8) 0.66
Hospitalization prior to ICU admission (n (%)) 31 (59.6) 33 (80.5) 0.03
Underlying disease(s)
 COPD (n (%)) 10 (19.2) 14 (34.1) 0.10
 Chronic renal failure (n (%)) 6 (11.8) 4 (9.7) 0.76
 Chronic cardiac disease (n (%)) 37 (72.5) 28 (68.3) 0.66
 Diabetes mellitus (n (%)) 20 (39.2) 9 (21.9) 0.07
 Cirrhosis (n (%)) 0 (0.0) 2 (4.9) 0.11
Immunosuppression (excepting steroids) (n (%)) 2 (4.9) 2 (3.9) 0.82
 Steroids (n (%)) 5 (9.8) 3 (7.3) 0.67
 Cancer (n (%)) 6 (11.8) 4 (9.8) 0.76
Nursing-home resident (n (%)) 1 (1.9) 1 (2.4) 0.86
Main admission diagnosis    0.20
 Respiratory distress (n (%)) 22 (42.3) 11 (26.8) 0.12
 Extrapulmonary sepsis (n (%)) 15 (28.8) 18 (43.9) 0.13
 Neurologic failure (n (%)) 4 (7.7) 6 (14.6) 0.28
 Abdominal surgery (n (%)) 0 (0.0) 2 (4.9) 0.11
 Miscellaneous (n (%)) 11 (21.1) 4 (9.8) 0.14
Renal failure on admission (Yes (%)) 29 (55.8) 21 (51.2) 0.66
Nasogastric tube (Yes (%)) 52 (100) 39 (95.1) 0.11
  1. Baseline characteristics according to statin continuation. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.